IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#849
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$11.5B
Michael Goettler
Viatris Inc. operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.
Headcount
37.0K
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = VTRS ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$VTRS Viatris Inc | 58 | 49 | 73 | 69 | - | 25.6x | -20.2% | -8.1% | 37.1% | -17.8% | -23.6% | -1.0% | 4.9% | 149.0x | $11.5B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Viatris Inc (VTRS) receives a "Hold" rating with a composite score of 58.4/100. It ranks #849 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
Pending Verification
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for VTRS.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 49 | 42 | +7ALPHA |
| MOMENTUM | 69 | 72 | -3NEUTRAL |
| VALUATION | 73 | 75 | -2NEUTRAL |
| INVESTMENT | 31 | 42 | -11DRAG |
| STABILITY | 75 | 78 | -3NEUTRAL |
| SHORT INT | 36 | 29 | +7ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 0.7% vs WACC 5.6% (spread -5.0%)
GM 37% vs sector 44%, OM -18% vs sector 3%
Capital turnover 0.28x, R&D intensity 6.5%
Rev growth -1%, 6yr history
Interest coverage 1.5x, Net debt/EBITDA 75.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Viatris Inc (VTRS) as a Hold with a composite score of 58.4/100 at a current price of $16.22. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Viatris Inc holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 58.4/100 places it at rank #849 in our full universe.
The near-term outlook is constructive, with revenue growing at -1% and momentum in the 69th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
High
Poor
Undervalued
Value factor score of 73 suggests attractive pricing.
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Leverage of 149% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
Viatris Inc represents a hold based on multi-factor quantitative performance.
Our model assigns Viatris Inc a Hold rating, with a composite score of 58.4/100 and 3 out of 5 stars. Ranked #849 of 7,333 stocks, VTRS presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 49/100, VTRS shows adequate but unremarkable business quality. The company reports a return on equity of -20.2% (sector avg: -1.9%), gross margins of 37.1% (sector avg: 44.1%), net margins of -23.6% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
VTRS carries a solid value score of 73/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include an EV/EBITDA of 25.64x, a P/B ratio of 1.20x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
Viatris Inc's investment score of 31/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -1.0% vs. a sector average of 6.7% and a return on assets of -8.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
VTRS demonstrates moderate momentum with a score of 69/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -1.0% year-over-year, while a beta of 0.87 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
VTRS shows good financial stability with a score of 75/100. Key stability metrics include a beta of 0.87 and a debt-to-equity ratio of 149.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
Viatris Inc's short interest score of 36/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 149.00x). At $11.5B (large-cap), VTRS carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Viatris Inc offers an attractive dividend yield of 4.9%, placing it among the higher-yielding stocks in its peer group. A yield this high can provide meaningful income, but investors should verify the payout is sustainable by examining the payout ratio, free cash flow coverage, and any history of dividend cuts.
Viatris Inc is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #849 of 7,333 overall (88th percentile). Key comparisons include ROE of -20.2% trailing the -1.9% sector median and operating margins of -17.8% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While VTRS currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Stability (75) vs Investment (31) — closing this gap could shift the rating.
EV/EBITDA 124% ABOVE SECTOR MEDIAN
ROE 965% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 16% BELOW SECTOR MEDIAN
Levi & Korsinsky, LLP has announced a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS), advising investors who suffered losses between August 8, 2024, and February 26, 2025, to contact them by June 3, 2025. The lawsuit alleges that Viatris misrepresented the impact of a warning letter from the FDA concerning its Indore, India facility, leading to a significant stock price drop following disappointing 2025 guidance. Affected shareholders may be entitled to compensation without out-of-pocket costs.
Theravance Biopharma, Inc. (TBPH) offers a compelling investment opportunity in the biotechnology sector, identified by a potential upside of 37.70% according to analyst targets. The company, known for its COPD medication YUPELRI and pipeline product Ampreloxetine, demonstrates strong revenue growth of 18.50% and a positive outlook from analysts. With its stock trading above moving averages and a reasonable forward P/E ratio, TBPH is positioned for future growth through innovation and strategic partnerships.
The article evaluates the State Street SPDR Portfolio S&P 500 High Dividend ETF (SPYD), highlighting it as a smart beta ETF focused on large-cap value with a high dividend yield. It details the fund's objective to track the S&P 500 High Dividend Index, its low expense ratio of 0.07%, and its sector allocations, including top holdings like CVS Health Corp. The report concludes that SPYD is a strong option for investors seeking to outperform the Style Box - Large Cap Value segment, offering diversified exposure and solid performance.
Viatris Inc. (VTRS) stock increased by 2.51% to $15.95 on Tuesday, marking its third consecutive day of gains. This rise occurred during a mixed trading session where the Dow Jones Industrial Average (DJIA) saw a slight increase, while the S&P 500 Index (SPX) experienced a decline. The company's performance outperformed the overall market trends for the day.
Viatris (VTRS) shares rose after UBS upgraded the stock to Buy from Neutral, increasing its price target to $11 from $8. The upgrade is based on a promising growth outlook and an expanding drug pipeline for the company.
Above 50MA
37.18%
Net New Highs
+51081